(Q28264860)

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Refractory mucosal candidiasis in advanced human immunodeficiency virus infection.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Refractory mucosal candidiasis in patients with human immunodeficiency virus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Emergence of oropharyngeal candidiasis caused by non-albicans species of Candida in HIV-infected patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Fluconazole compared with endoscopy for human immunodeficiency virus-infected patients with esophageal symptoms

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Guidelines for treatment of candidiasis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Echinocandins: ask not what they can do for esophageal candidiasis--ask what studies of esophageal candidiasis can do for them

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Decline in esophageal candidiasis and use of antimycotics in European patients with HIV.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Attributable mortality of nosocomial candidemia, revisited

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Deeply invasive candidiasis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Aspergillosis case-fatality rate: systematic review of the literature

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

31 March 2020

Invasive aspergillosis

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Cryptococcal fungemia in a neutropenic patient with AIDS while receiving caspofungin

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Candida biofilm resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Caspofungin versus liposomal amphotericin B for empirical therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Guidelines for the management of deep mycosis in neutropenic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Antifungal therapy in patients with fever and neutropenia--more rational and less empirical?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Safety and tolerability of caspofungin acetate in the treatment of fungal infections

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Prophylaxis and treatment of invasive candidiasis in the intensive care setting

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Prophylaxis for invasive candidiasis in the intensive care unit: is it time?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Combination antifungal therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Combination treatment of invasive fungal infections

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Antifungal combination therapy: clinical potential

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Rationale for combination antifungal therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Combination antifungal therapy for invasive aspergillosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

Observations on spiraling empiricism: its causes, allure, and perils, with particular reference to antibiotic therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050464.P2